US2011172150A1PendingUtilityA1

Tissue regeneration method

45
Assignee: BADER AUGUSTINUSPriority: Dec 30, 2003Filed: Mar 21, 2011Published: Jul 14, 2011
Est. expiryDec 30, 2023(expired)· nominal 20-yr term from priority
Inventors:Augustinus Bader
A61P 5/00A61P 43/00A61P 5/14A61P 9/00A61P 41/00A61P 37/00A61P 9/14A61P 5/48A61P 35/00A61P 3/10A61P 27/16A61P 27/02A61P 25/00A61P 13/02A61P 17/02A61P 11/00A61P 13/12A61P 1/02A61P 17/00A61P 11/04A61P 1/18A61P 15/14A61P 13/08A61P 19/02A61P 19/04A61P 13/10A61P 15/00A61P 11/02A61P 1/04A61P 15/08A61P 17/14A61P 1/16A61P 21/00A61P 19/00A61K 38/1816A61L 27/54A61L 27/3804A61K 38/196A61K 35/407A61L 2300/414
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to the use of haematopoietic growth factors, in particular erythropoietin (EPO) and thrombopoietin (TPO), or derivatives analogues or parts thereof, for promoting structural tissue regeneration.

Claims

exact text as granted — not AI-modified
1 - 36 . (canceled) 
     
     
         37 . A method for healing of burn wounds in an individual using a skin graft, the method comprising topically applying erythropoietin (EPO) to said wound and applying said skin graft to said wound. 
     
     
         38 . The method of  claim 37 , wherein said EPO has additional glycosylation sites compared with native EPO. 
     
     
         39 . The method of  claim 37 , wherein said EPO is conjugated with polyethylene glycol. 
     
     
         40 . A method for promoting structural liver tissue regeneration in a subject, the method comprising contacting liver tissue in said subject with EPO. 
     
     
         41 . The method of  claim 40 , wherein said subject has liver cirrhosis, hepatitis, acute liver failure, or chronic liver failure. 
     
     
         42 . The method of  claim 40 , wherein said liver tissue has been resected. 
     
     
         43 . The method of  claim 42 , wherein said subject had a benign or malignant tumor prior to resection. 
     
     
         44 . The method of  claim 40 , further comprising administering a cytostatic agent to said subject. 
     
     
         45 . The method of  claim 40 , wherein said EPO is administered topically. 
     
     
         46 . The method of  claim 40 , wherein said EPO is administered systemically. 
     
     
         47 . The method of  claim 40 , wherein said EPO has additional glycosylation sites compared with native EPO. 
     
     
         48 . The method of  claim 40 , wherein said EPO is conjugated with polyethylene glycol.

Join the waitlist — get patent alerts

Track US2011172150A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.